Cardiac Rehabilitation in Chagas Heart Failure

Status Completed

Clinical Trial Summary

Due to the lack of information in the literature about the role of cardiac rehabilitation on Chagas heart failure, the aim of the present study was to evaluate the effects of a cardiac exercise program on functional capacity, cardiac function, respiratory muscle strength, body composition, biomarkers and quality of life among Chagas heart failure patients.

Clinical Trial Description

The present study consisted in a pre/post single-arm intervention study conducted at the Evandro Chagas National Institute of Infectious Disease (INI), located on Rio de Janeiro, Brazil. INI is a national reference center for treatment and research in infectious diseases and tropical medicine in Brazil, which follows a large cohort of patients with Chagas disease, all of them diagnosed by two simultaneously positive serological tests (enzyme-linked immunosorbent assay and indirect immunofluorescence). Patients included in the study were submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during an 8-month period. Nutritional and pharmaceutical counseling were also monthly provided during the follow-up and consisted on general guidance about adequate eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.Patients included in the study were followed during an 8-month period in which evaluations of functional capacity (maximal progressive cardiopulmonary exercise test), muscle respiratory strength (manovacuometry) and body composition (anthropometry and skinfolds) were performed at baseline, after four months and at the end of follow-up. Assessments of cardiac function (bidimensional echocardiography), biomarkers (lipid profile, glucose and glycated hemoglobin) and quality of life (Minnesota Living with Heart Failure questionnaire) were taken at baseline and after eight months of follow-up. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02516293
Study type	Interventional
Source	Evandro Chagas National Institute of Infectious Disease
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	May 2013
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01162967` - Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole	Phase 2
Completed	`NCT00023556` - Genetic Architecture of Heart Disease in Rural Brazil	N/A
Active, not recruiting	`NCT04024163` - Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease	Phase 3
Recruiting	`NCT05868005` - Delivering a Multi-disease Screening Tool to Migrant Populations	N/A
Completed	`NCT03892213` - Pharmacokinetic Drug-Drug Interaction Study	Phase 1
Recruiting	`NCT00875173` - Selenium Treatment and Chagasic Cardiopathy (STCC)	Phase 3
Recruiting	`NCT03704181` - Colchicine for Patients With Chagas´ Disease( B1 Stage)	Phase 2
Active, not recruiting	`NCT03378661` - BENDITA BEnznidazole New Doses Improved Treatment and Associations	Phase 2
Completed	`NCT01927224` - Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients	Phase 1
Completed	`NCT01006486` - Outcomes of an Anticoagulation Clinic in an University Hospital	Phase 4
Completed	`NCT00123916` - BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease	Phase 3
Completed	`NCT02517632` - Physical Exercise Program in Chronic Chagas Heart Disease	Phase 3
Recruiting	`NCT02099903` - Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease	N/A
Completed	`NCT01874795` - Effect of Ganglionar Electrical Stimulation on Central Arterial Pressure	N/A
Completed	`NCT01006473` - Exercise Training in Chagas Cardiomyopathy	Phase 4
Completed	`NCT02386358` - Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial	Phase 3
Completed	`NCT02346123` - Determination of Genetic Polymorphisms in Chronic Chagas Cardiomyopathy	N/A
Recruiting	`NCT02295215` - Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction	N/A
Completed	`NCT03350295` - Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg	Phase 1
Recruiting	`NCT03672487` - Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.